Acta paediatrica (Oslo, Norway : 1992) 2017 07 16() doi 10.1111/apa.13992
Lactobacillus reuteri is a Gram-positive bacterium that naturally inhabits the human intestinal tract. This study assessed how effectively the probiotic Lactobacilllus reuteri DSM 17938 managed childhood functional abdominal pain (FAP).
We recruited 54 children with a mean age 9.1±3.8 years, who were diagnosed with FAP in the outpatient clinics of three university hospitals in Greece, Slovenia and Poland, according to the Rome III criteria, from January 2013 to December 2015. They were randomly assigned to receive either 2×10(8) colony-forming units of L. reuteri (n=27) or a placebo (n=27) for four weeks.
Both L. reuteri and the placebo significantly reduced the frequency and intensity of abdominal pain episodes at four and eight weeks (all p<0.001). L. reuteri decreased the number of school absences and the use of pain relieving drugs at four weeks and eight weeks, unlike the placebo, which achieved non significant results. However the difference between the groups did not reach significance. In contrast, L. reuteri, improved the child's and family's normal activities. No side effects were recorded. CONCLUSION
Both L. reuteri and the placebo were effective in alleviating pain in children with FAP but only L. reuteri, improved the child’s and family’s normal activities. This article is protected by copyright. All rights reserved.